Clinical Scorecard: A Bacteroides strain derived from humans reduces depressive-like behaviors in a rat model subjected to social defeat stress
At a Glance
Category
Detail
Condition
Depression characterized by persistent sadness, anhedonia, and altered mood states
Key Mechanisms
Gut-brain axis modulation via microbiome-produced GABA affecting neurotransmission and neuroinflammation
Target Population
Individuals with depression potentially linked to gut microbiome disturbances
Care Setting
Preclinical research setting with translational potential for clinical depression treatment
Key Highlights
Oral administration of human-derived GABA-producing Bacteroides salyersiae HB32 reduces depressive-like behaviors in rats exposed to social defeat stress.
B. salyersiae HB32 produces bioactive metabolites including GABA, short-chain fatty acids, and vitamins that may modulate the gut-brain axis.
The social defeat model in rats mimics human depression triggers and allows assessment of microbiome interventions compared to ketamine treatment.
Guideline-Based Recommendations
Diagnosis
Consider multifactorial assessment including mood symptoms, stress exposure, and potential gastrointestinal disturbances.
Management
Explore microbiome-targeted therapies such as oral administration of GABA-producing Bacteroides strains as adjuncts to conventional treatments.
Use of ketamine as a comparator treatment for rapid antidepressant effects.
Monitoring & Follow-up
Monitor behavioral changes including anhedonia and reward learning deficits in preclinical models.
Assess gut microbiome composition and metabolite profiles to evaluate intervention effects.
Risks
Potential risks of live bacterial administration include infection or dysbiosis; inactivated bacterial preparations may mitigate viability concerns.
Patient & Prescribing Data
Preclinical rat model of depression induced by repeated social defeat stress
Daily oral gavage of 1 × 10^9 CFU of live or inactivated B. salyersiae HB32 for 7 days showed behavioral improvements comparable to subanesthetic ketamine dosing.
Clinical Best Practices
Use ethologically relevant animal models such as repeated social defeat to study depression and microbiome interventions.
Prepare bacterial strains under anaerobic conditions ensuring viability and confirm inactivation for control preparations.
Incorporate multi-omics analyses and vagotomy to elucidate gut-brain axis mechanisms.
Ensure humane animal care and monitor for distress throughout experimental protocols.
by Marisol I. Dothard, Mariaelena Caboni, Daniel Norment, Nolan Sigmund, Sarah M. Allard, Jack A. Gilbert, Ekaterina Gavrish, Gabriel Al-Ghalith, Andre Der-Avakian, Philip Strandwitz
